Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



December 2015: AWSMG approvals

The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG):

  • Abasaglar (a biosimilar of insulin glargine; Eli Lilly and Company) for diabetes mellitus in patients aged 2 years and above.
  • Sucroferric oxyhydroxide (Velphoro; Vifor Fresenius Medical Care Renal Pharma) for controlling serum phosphorus levels in adults with chronic kidney disease who are on haemodialysis or peritoneal dialysis where non-calcium based phosphate binders are considered appropriate.
  • Tedizolid phosphate (Sivextro; Merck Sharp & Dohme) to treat adults with acute bacterial and skin structure infections caused by methicillin-resistant Staphylococcus aureus (only when advised by a local microbiologist).
  • Raltegravir granules (Isentress; Merck Sharp & Dohme) for oral suspension to treat human immunodeficiency virus infections.
  • Adalimumab (Humira; AbbVie) to treat severe plaque psoriasis in children and adolescents aged 4 years and above.
  • Tinzaparin (Innohep; Leo Laboratories) for the extended treatment or prevention of symptomatic venous thromboembolism in adults with solid tumours.
  • Denosumab (Prolia; Amgen) for adults and skeletally mature adolescents with an unresectable giant cell tumour of bone (only via the approved patient access scheme).

Full details of restrictions are available from the AWMSG website ( 

Citation: The Pharmaceutical Journal URI: 20200384

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.